

# Daniel A Scott

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4749159/publications.pdf>

Version: 2024-02-01

61  
papers

3,263  
citations

236925

25  
h-index

149698

56  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3131  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. <i>New England Journal of Medicine</i> , 2015, 372, 1114-1125.	27.0	957
2	Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults. <i>Vaccine</i> , 2013, 31, 3577-3584.	3.8	198
3	Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 952-962.	5.8	192
4	Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2013, 31, 3585-3593.	3.8	156
5	Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. <i>Vaccine</i> , 2014, 32, 2364-2374.	3.8	136
6	Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. <i>Vaccine</i> , 2013, 31, 3594-3602.	3.8	132
7	Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers. <i>Vaccine Journal</i> , 2010, 17, 1017-1026.	3.1	130
8	Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. <i>Clinical Infectious Diseases</i> , 2021, 73, e1489-e1497.	5.8	98
9	Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. <i>Vaccine</i> , 2019, 37, 6201-6207.	3.8	87
10	Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 313-323.	5.8	86
11	Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible <i>Streptococcus pneumoniae</i> . <i>Journal of Infectious Diseases</i> , 2015, 211, 1144-1153.	4.0	66
12	Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. <i>Vaccine Journal</i> , 2012, 19, 1296-1303.	3.1	64
13	Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM197 conjugate vaccine. <i>Annals of the New York Academy of Sciences</i> , 2012, 1263, 15-26.	3.8	64
14	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. <i>Clinical Infectious Diseases</i> , 2022, 75, 390-398.	5.8	60
15	Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. <i>Journal of Infectious Diseases</i> , 2015, 212, 18-27.	4.0	49
16	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naïve to pneumococcal vaccination. <i>Aids</i> , 2015, 29, 1345-1354.	2.2	47
17	A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia) Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1017-1026.	1.2	47
18	Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. <i>Vaccine</i> , 2018, 36, 1477-1483.	3.8	39

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2198-2206.	3.3	38
20	Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPITA). <i>Clinical Infectious Diseases</i> , 2017, 65, 787-795.	5.8	36
21	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 18 through 49 years of age. <i>Vaccine</i> , 2021, 39, 5428-5435.	3.8	36
22	Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. <i>Vaccine</i> , 2016, 34, 4313-4320.	3.8	33
23	A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. <i>Vaccine</i> , 2021, 39, 7494-7502.	3.8	33
24	13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1427-1436.	1.5	31
25	Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1343-1353.	3.3	28
26	A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. <i>Vaccine</i> , 2017, 35, 1926-1935.	3.8	27
27	Post Hoc Analysis of a Randomized Double-Blind Trial of the Correlation of Functional and Binding Antibody Responses Elicited by 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines and Association with Nasopharyngeal Colonization. <i>Vaccine Journal</i> , 2014, 21, 1277-1281.	3.1	25
28	13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Naïve to 7-valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 183-189.	2.0	25
29	Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. <i>Vaccine</i> , 2014, 32, 417-424.	3.8	23
30	Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. <i>Vaccine</i> , 2016, 34, 3454-3462.	3.8	22
31	Diabetes mellitus as a vaccine-effect modifier: a review. <i>Expert Review of Vaccines</i> , 2020, 19, 445-453.	4.4	20
32	Pneumococcal conjugate vaccine use in adults. <i>Expert Review of Vaccines</i> , 2016, 15, 279-293.	4.4	18
33	Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. <i>Vaccine</i> , 2015, 33, 1719-1725.	3.8	17
34	Safety of 13-valent pneumococcal conjugate vaccine in infants and children: Meta-analysis of 13 clinical trials in 9 countries. <i>Vaccine</i> , 2013, 31, 5289-5295.	3.8	16
35	Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 509-516.	2.0	16
36	Open-Label Trial of Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Adults ≥50 Years of Age in Mexico. <i>Vaccine Journal</i> , 2015, 22, 185-192.	3.1	16

#	ARTICLE	IF	CITATIONS
37	PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. <i>Vaccine</i> , 2017, 35, 945-950.	3.8	16
38	Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. <i>Vaccine</i> , 2011, 29, 2947-2955.	3.8	15
39	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1850-1858.	3.3	15
40	Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 444-451.	3.3	14
41	Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2065-2071.	3.3	13
42	Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 326-332.	2.0	12
43	Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age. <i>Expert Review of Vaccines</i> , 2018, 17, 45-55.	4.4	12
44	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. <i>Vaccine</i> , 2017, 35, 3256-3263.	3.8	11
45	Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. <i>Vaccine</i> , 2018, 36, 473-478.	3.8	11
46	Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 Given to Healthy Infants at 2, 3, 4 and 12 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 180-185.	2.0	8
47	Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose. <i>Clinical Infectious Diseases</i> , 2021, 72, 448-454.	5.8	8
48	3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older. <i>Open Forum Infectious Diseases</i> , 2020, 7, S2-S2.	0.9	8
49	Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population. <i>Vaccine</i> , 2018, 36, 8084-8093.	3.8	7
50	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2758-2772.	3.3	7
51	A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2249-2256.	3.3	7
52	Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23-Valent Pneumococcal Polysaccharide Vaccine: An Open-Label Trial. <i>World Journal of Vaccines</i> , 2013, 03, 123-129.	0.8	7
53	Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1948-1956.	3.3	6
54	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1150-1158.	2.0	6

#	ARTICLE	IF	CITATIONS
55	Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 575-583.	3.3	5
56	Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China. <i>Vaccine</i> , 2016, 34, 5359-5365.	3.8	2
57	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2691-2699.	3.3	2
58	A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines. <i>Vaccine</i> , 2021, 39, 6414-6421.	3.8	2
59	Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 617 Years of Age in India. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e283-e285.	2.0	1
60	A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India. <i>Vaccine</i> , 2021, 39, 5313-5317.	3.8	0
61	Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study. <i>Vaccine</i> , 2021, 39, 6787-6795.	3.8	0